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Prophylactic oxytocin: Before 
or after placental delivery?
Evidence-based answer
Either is fi ne. 
 Timing alone doesn’t infl uence the 
drug’s effi cacy in preventing postpartum 
bleeding (strength of recommendation: 
B, randomized controlled trial [RCT] and 
prospective cohort studies). 
❚ Evidence summary
The prophylactic use of oxytocic drugs re-
duces the risk of postpartum hemorrhage 
(PPH) by about 40% and has been widely 
adopted as a routine policy in the active 
management of the third stage of labor.1 
A number of studies have evaluated the 
timing of oxytocin after delivery (TABLE). 
Which timing is best? 
It depends on the study 
A well-constructed double-blinded RCT 
found no signifi cant difference in the in-
cidence of PPH when oxytocin was given 
after delivery of the anterior shoulder or 
the placenta.2 The study included 1486 
patients; 745 received 20 units of oxy-
tocin on delivery of the anterior shoul-
der, and 741 received an identical dose 
of oxytocin on delivery of the placenta. 
The incidence of PPH was 5.4% for the 
anterior shoulder group and 5.8% for 
the placenta group (P=.72). Likewise, no 
signifi cant difference between the groups 
was noted in the proportion of women 
with estimated blood loss (EBL) ≥500 
mL (7.5% vs 9.7%; P=.15). 
A much smaller double-blinded RCT 
found that PPH occurred signifi cantly 
less often when oxytocin was delayed 
until after delivery of the placenta.3 The 
study comprised 51 patients; 27 received 
10 units of oxytocin on delivery of the an-
terior shoulder and 24 received an iden-
tical dose after delivery of the placenta. 
The incidence of PPH ≥500 mL was 0% 
when oxytocin was given after delivery 
of the placenta vs 14.8% when it was 
given on delivery of the anterior shoulder 
(P=.049). However, the study was limited 
by its size and potential inaccuracies in 
estimating blood loss. 
A prospective cohort study noted a 
signifi cant reduction in the risk of PPH 
when oxytocin was given after delivery 
of the anterior shoulder, compared with 
the placenta.4 In this study, 82 patients re-
ceived 5 units of oxytocin on delivery of 
the anterior shoulder, and 52 received an 
identical dose after delivery of the placen-
ta. The incidence of PPH ≥500 mL was 
7.3% in the anterior shoulder group and 
19.2% in the placenta group. However, 
the study was not blinded and was lim-
ited by its small sample size. 
Two earlier studies, an RCT and a 
prospective cohort study, concluded 
that oxytocin is more effective in reduc-
ing PPH when given before placental 
delivery (after delivery of the anterior 
shoulder and head, respectively).5,6 Nei-
ther of these studies was blinded nor 
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controlled for nonpharmacologic inter-
ventions, however. 
Recommendations
The American College of Obstetricians 
and Gynecologists (ACOG) states that 
ongoing blood loss accompanied by de-
creased uterine tone requires uterotonic 
agents as fi rst-line treatment for PPH.7 
ACOG doesn’t make specifi c recommen-
dations regarding the timing of oxytocin 
administration. 
The American Academy of Family 
Physicians (AAFP) recommends oxyto-
cin as the uterotonic agent of choice for 
preventing PPH.8 The AAFP further ad-
vocates active management of the third 
stage of labor to decrease PPH by admin-
istering oxytocin as soon as possible af-
ter delivery of the anterior shoulder and 
before delivery of the placenta.
The World Health Organization 
(WHO) also recommends oxytocin as 
the uterotonic of choice.9 WHO advo-
cates administration within 1 minute of 
delivery of the baby. ■
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What studies say about the timing of oxytocin and PPH risk
STUDY TYPE 
(YEAR)
OXYTOCIN GIVEN AFTER
OUTCOMES (RISK OF PPH)
DELIVERY OF ANTERIOR 
SHOULDER (N) 
DELIVERY OF 
PLACENTA (N)
DBRCT (2001)2 745 741 No difference
(OR=0.92; 95% CI, 0.59-1.43)
DBRCT (2004)3 27 24 Incidence lower when given after 
delivery of placenta (P=.049)
Cohort (2006)4 82 52 Incidence lower when given 
after delivery of anterior shoulder 
(OR=0.33; 95% CI, 0.11-0.98)
RCT (1997)5 827 821 Incidence lower when given 
after delivery of anterior shoulder 
(OR=0.50; 95% CI, 0.34-0.73)
Cohort (1996)6 524 (given after 
delivery of head)
478 Incidence lower when given 
after delivery of head 
(OR=0.60; 95% CI, 0.41-0.87)
CI, confi dence interval; DBRCT, double-blinded randomized controlled trial; OR, odds ratio; PPH, postpartum 
hemorrhage; RCT, randomized controlled trial. 
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Prophylactic use 
of oxytocic drugs 
reduces the risk 
of postpartum 
hemorrhage by 
about 40% 
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